Can anti-IgE and anti-IL-5 monoclonal antibodies be protective against household transmission of SARS-CoV-2?

Emel ATAYIK; Gökhan AYTEKİN

doi:https://doi.org/10.32322/jhsm.1026619

Makale detayları

Can anti-IgE and anti-IL-5 monoclonal antibodies be protective against household transmission of SARS-CoV-2?

Yazarlar:

Emel ATAYIK | Gökhan AYTEKİN

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Journal of Health Sciences and Medicine 2022 Vol.5 Issue 2, pp.698-701

Belge Tipi:

Makale

Yayın Tarihi:

3/2022

Belge Dili:

İngilizce

Document ID (Org No.):

2000481653

Sıklık:

İki Aylık

eISSN:

2636-8579

DOI:

https://doi.org/10.32322/jhsm.1026619

Özet:

 

Coronavirus disease 2019 (COVID-19) is the general term used for pneumonia caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Keeping the infected individuals in quarantine is very effective in preventing the spread of the disease but isolation and quarantine period increase the risk of household transmission. By December 2020, the rate of household transmission of SARS-CoV-2 has reached up to 85%. Both omalizumab and mepolizumab are used for the treatment of severe persistent asthma. In addition, omalizumab also has an indication for use in chronic urticaria. Both medications have been shown to have some antiviral effects. So, we aimed to discuss potential protective effects of these agents against household transmission of SARS-CoV-2 by reporting six different patients who remained uninfected despite PCR (Polymerase Chain Reaction) (+) SARS-CoV-2 individuals at home and were being treated with monoclonal antibodies.

Makale detayları

Can anti-IgE and anti-IL-5 monoclonal antibodies be protective against household transmission of SARS-CoV-2?

Yazarlar: Emel ATAYIK | Gökhan AYTEKİN

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Sağlık teşvikleri

Dergi: Journal of Health Sciences and Medicine 2022 Vol.5 Issue 2, pp.698-701

Belge Tipi: Makale

Yayın Tarihi: 3/2022

Belge Dili: İngilizce

Document ID (Org No.): 2000481653

Sıklık: İki Aylık

eISSN: 2636-8579

DOI: https://doi.org/10.32322/jhsm.1026619

Sayı

Yazarlar:

Emel ATAYIK | Gökhan AYTEKİN

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Journal of Health Sciences and Medicine 2022 Vol.5 Issue 2, pp.698-701

Belge Tipi:

Makale

Yayın Tarihi:

3/2022

Belge Dili:

İngilizce

Document ID (Org No.):

2000481653

Sıklık:

İki Aylık

eISSN:

2636-8579

DOI:

https://doi.org/10.32322/jhsm.1026619